Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.

In the case of patients with HF at baseline ( n =706; 10.1%), empagliflozin also reduced both HFH rate (10.4% versus 12.4%; HR 0.75, 95% CI 0.48–1.19) and CV mortality (8.2% versus 11.1%; HR 0.71, 95% CI 0.43–1.16), though CV mortality did not reach statistical significance. 19 , 20 The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program 23 integrated data from two trials involving a total of 10,142 participants with T2DM and high CV risk.

also in 111,027 other papers